Jan 2, 2026 09:17AM Outlook Therapeutics Inc. (OTLK) PT Lowered to $0.50 at H.C. Wainwright

Jan 2, 2026 07:02AM Baidu, ASML, furniture stocks rise; Outlook Therapeutics sinks

Dec 31, 2025 04:15PM Outlook Therapeutics receives FDA rejection for eye drug application

Dec 19, 2025 08:05AM Outlook Therapeutics reports $62.4 million loss for fiscal 2025

Nov 13, 2025 08:31AM Outlook Therapeutics gets FDA acceptance for wet AMD drug application

Nov 3, 2025 08:35AM Outlook Therapeutics resubmits drug application to FDA after September meeting

Sep 30, 2025 06:54AM H.C. Wainwright Reiterates Neutral Rating on Outlook Therapeutics Incs. (OTLK)

Sep 29, 2025 04:03PM Outlook Therapeutics Incs. (OTLK) PT Raised to $13 at Brookline Capital Markets

Sep 29, 2025 08:45AM Outlook Therapeutics plans BLA resubmission after FDA meeting

Sep 2, 2025 08:35AM Outlook Therapeutics requests FDA meeting on drug application rejection

Aug 29, 2025 06:51AM H.C. Wainwright Downgrades Outlook Therapeutics Incs. (OTLK) to Neutral

Aug 28, 2025 12:43PM Guggenheim Downgrades Outlook Therapeutics Incs. (OTLK) to Neutral

Aug 28, 2025 06:53AM Outlook Therapeutics receives FDA rejection letter for eye drug

Aug 14, 2025 04:15PM Outlook Therapeutics (OTLK) Misses Q3 EPS by 44c

Jul 22, 2025 08:40AM JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live

Jul 1, 2025 08:06AM Outlook Therapeutics (OTLK) Appoints Bob Jahr as CEO

Jun 13, 2025 06:53AM Outlook Therapeutics Incs. (OTLK) PT Lowered to $10 at Brookline Capital Markets

Jun 10, 2025 08:06AM Outlook Therapeutics (OTLK) Announces SMC Recommendation of LYTENAVA for the Treatment of Wet AMD

Jun 6, 2025 05:23AM Outlook Therapeutics Incs. (OTLK) PT Lowered to $21 at Ascendiant Capital

Jun 2, 2025 07:03AM Outlook Therapeutics (OTLK) Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

May 23, 2025 06:39AM Outlook Therapeutics (OTLK) Announces Pricing of $13.0 Million Public Offering

May 22, 2025 04:05PM Outlook Therapeutics (OTLK) propses public offering

Apr 9, 2025 07:21AM Guggenheim Reiterates Buy Rating on Outlook Therapeutics Incs. (OTLK)

Apr 8, 2025 05:02PM Outlook Therapeutics (OTLK) Announces FDA Set August 27, 2025 as PDUFA for ONS-5010

Apr 8, 2025 08:45AM Outlook Therapeutics (OTLK) Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Feb 28, 2025 08:05AM Outlook Therapeutics (OTLK) Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Feb 18, 2025 06:44AM Outlook Therapeutics Incs. (OTLK) PT Lowered to $3 at H.C. Wainwright

Jan 31, 2025 08:05AM Outlook Therapeutics (OTLK) Appoints Faisal G. Sukhtian as Chairman

Jan 23, 2025 09:05AM Outlook Therapeutics (OTLK) Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Jan 16, 2025 06:01AM Outlook Therapeutics (OTLK) Reports Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Dec 27, 2024 08:07AM Outlook Therapeutics (OTLK) Reports Q4, Provides Corporate Update

Dec 13, 2024 04:33PM Outlook Therapeutics (OTLK) Streamlines Operations

Dec 4, 2024 08:06AM Outlook Therapeutics (OTLK) Announces NICE Recommendation of LYTENAVA for the Treatment of Wet AMD

Dec 3, 2024 04:31PM Outlook Therapeutics (OTLK) Announces Executive Leadership Transition

Dec 2, 2024 03:49AM Chardan Capital Markets Downgrades Outlook Therapeutics Incs. (OTLK) to Neutral

Nov 29, 2024 06:32AM H.C. Wainwright Reiterates Buy Rating on Outlook Therapeutics Incs. (OTLK)

Nov 29, 2024 06:02AM Outlook Therapeutics Incs. (OTLK) PT Lowered to $9 at BTIG

Nov 27, 2024 06:50AM Outlook Therapeutics (OTLK) Reports Prelim Topline Results of NORSE EIGHT Trial

Sep 4, 2024 03:27PM Outlook Therapeutics (OTLK) November 7.5 calls active as share price up 8.7%

Sep 4, 2024 08:35AM Outlook Therapeutics (OTLK) Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

Aug 14, 2024 10:59AM Outlook Therapeutics, Inc. (OTLK) Tops Q2 EPS by 9c

Jul 8, 2024 08:35AM Outlook Therapeutics (OTLK) Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD